From Edwards to Insulet: Three key medical device cases of 2025

Edwards v Meril, Teva and the FTC, and modified jury verdicts—lawyers from WilmerHale provide a review of the key cases of the year and their implications.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Edwards v Meril: 3 insights from the UPC Court of Appeal’s decision

19 December 2025 With its landmark ruling, the court has delivered guidance for patentees and litigants— including three takeaways for counsel and rights holders, explain Tobias Wuttke and Axel Berger of Bardehle Pagenberg.

Americas

Teva scrubs 200-plus Orange Book patents after FTC turns the screw

11 December 2025 Israeli drug maker bows to FTC pressure, removing scores of “improperly listed” patents in boon for generic manufacturers.

Europe

Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO

24 April 2025 Following the Unified Patent Court’s recent Meril v Edwards decision, Agathe Michel-de Cazotte & Ben Chapman of Carpmaels & Ransford examine the court’s treatment of obviousness to date.

More features

Edwards v Meril: Behind the UPC’s landmark medtech showdown

5 ways the USPTO director is changing US innovation

EU unveils sweeping pharma, biotech, and medical device reforms

Mirum targets generics in quartet of suits over liver treatment

Hogan Lovells and Cadwalader strike historic deal to create $3.6bn firm

WATCH: Enabling success — overcoming §112 in the new era of life sciences patents

WATCH: Clinical trials and their impact on patentability in Europe

WATCH: “Try and see” – an underestimated standard for obviousness before the EPO?

From Edwards to Insulet: Three key medical device cases of 2025

More on this story

Editor's picks

Editor's picks

More features